用拜耳利伐沙班治疗静脉血栓需要吃多久？

(Rivaroxaban) is a new anticoagulant drug that is rapidly absorbed after oral administration and has an average half-life of 7 to 13 hours. It has the advantages of high bioavailability, stable anticoagulant effect, high selectivity, and obvious therapeutic effect. Patients can benefit greatly from taking this drug consistently. Under normal circumstances, as long as there are no obvious contraindications and the instructions are strictly followed or the doctor's advice is followed, patients with indications can use rivaroxaban tablets for a long time. Based on the different conditions and constitutions of individual patients, the final length of time required to treat venous thrombosis with Bayer Rivaroxaban will vary from person to person.

Germany's Bayer Healthcare, as one of the top three foreign pharmaceutical companies in China, saw its prescription drug business grow by 22% in 2010, far exceeding its global growth rate of 5.8%. The Chinese market has also become the main growth point for its global performance. This data also strengthens Bayer's determination and investment in developing the Chinese pharmaceutical market. The launch of Bayer's rivaroxaban in Germany not only provides new treatment options for domestic patients, but also brings huge market value, and the market prospects are broad.

Under normal circumstances, if the patient's wound has stopped bleeding, the first medication should be administered between 6 and 10 hours after the operation. The recommended dose is 10 mg orally, once a day. When actually taking the drug, patients can take it with meals or alone.

In terms of safety, domestic research statistics on bleeding complications after the use of rivaroxaban have found no increase in fatal bleeding and intracranial bleeding. Bleeding complications such as urinary tract bleeding and hemorrhoidal bleeding all have possible causes and the bleeding stops after treatment. Therefore, oral rivaroxaban is safer as an anticoagulant. Oral administration of Rivaroxaban does not require routine monitoring, and the anti-Factor Xa chromogenic test can be used to quantitatively determine plasma concentrations of Factor Xa inhibitors when bleeding induced by Rivaroxaban is suspected.

Recommended hot articles: /newsDetail/96967.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.